A Phase 2 interventional study of Prednisolone and dipyridamole in Rheumatoid Arthritis, sponsored by Zalicus. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-15.
Sponsored by Zalicus · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 216th largest by enrollment of the 771 interventional ones that give a count, is one of 70 that started in 2011, is one of 215 in phase 2, and was the 401st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:
Tufts Medical Center · Sites in United States
Ages 18+
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Bristol-Myers Squibb · Sites in United States, Belgium, Brazil and 8 more countries
Ages 18–65
Fate Therapeutics · Sites in United States
Ages 18–70
PTC Therapeutics · Sites in United States, Georgia, Mauritius and 1 more country
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
975 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 161 · Phase 2 252 · Phase 3 172 · Phase 4 61
First in 1991; this study’s year is marked. 70 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 294 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 120 across the 771 interventional studies, 200 across the 199 observational. Of the 802 that completed or were terminated, 417 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
629 of 975 have an industry lead sponsor. The 10 most frequent:
Zalicus is the lead sponsor of 12 studies on the registry; none are open to participants now.
Zalicus has 4 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
37 of the studies in Arthritis, Rheumatoid with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06201416Sonoma Biotherapeutics, Inc.Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis | 2026-11 |
| NCT05961592Rise Therapeutics LLCR-2487 in Patients With Rheumatoid Arthritis | 2026-11-30 |
| NCT03409718Zimmer BiometDatabase Retrieval for the Comprehensive Shoulder | 2026-12 |
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
Add all 37 to your calendar (.ics) → With an account.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Thus study will test an experimental drug called Z-102 (combination of prednisolone and dipyridamole) to treat patients with moderate to severe rheumatoid arthritis.
The primary objective of the study was to demonstrate the efficacy of Z102 (2.7 mg prednisolone/360 mg dipyridamole) versus placebo on the Disease Activity Score 28 using C reactive protein (DAS28-CRP) in subjects with rheumatoid arthritis at the study endpoint of 12 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prednisolone 2.7 mg daily for 12 weeks
Drug: Prednisolone
Dipyridamole 360 mg daily for 12 weeks
Drug: dipyridamole
Prednisone 5 mg daily for 12 weeks
Drug: Prednisone
Prednisolone 2.7 mg plus dipyridamole 360 mg daily for 12 weeks
Drug: Z102
Placebo daily for 12 weeks
Other: placebo
Prednisolone 2.7 mg daily
dipyridamole 360 mg daily
Prednisone 5 mg daily
Prednisolone 2.7 mg plus dipyridamole 360 mg daily
Also known as: prednisolone, dipyridamole
Change From Baseline in DAS28-CRP at 12 Weeks
The primary efficacy endpoint was the mean change in Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12. The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤3.2 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.
Time frame: baseline to week 12
Change From Baseline in DAS28-CRP Individual Components at 12 Weeks
The mean change in the individual components of the Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12 which included individual assessment of Tender Joint Count (28-joint assessment), Swollen Joint Count (28-joint assessment), Patient Global Assessment of Disease Activity and absolute CRP level. In each case, higher scores indicate more disease activity. The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity.
Time frame: Baseline to week 12
Percentage of Subjects Achieving ACR20, ACR50 and ACR70 at 12 Weeks
The American College of Rheumatology (ACR) 20 is a widely accepted composite index of improvement in RA proposed by the ACR (Fransen and van Riel 2009). ACR20 refers to a composite improvement of 20% in swollen joint count, tender joint count, and 3 or more of the following 5 measures:Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient Pain VAS, Patient's self-addressed disability (HAQ) (Arnet 1988 and Felson 1995), Acute-phase reactant (ESR or CRP) The ACR 50 and ACR 70 are similar tools, used to indicate 50% and 70% improvement, respectively.
Time frame: Week 12
Multidimensional Assessment of Fatigue (MAF) at Week 12
The Multidimensional Assessment of Fatigue (MAF) scale contains 16 items and measures four dimensions of fatigue: severity (#1-2), distress (#3), degree of interference in activities of daily living (#4-14), and timing (#15-16). Fourteen items contain numerical rating scales (#1-14) and two items have multiple-choice responses (#15-16). Respondents are asked to reflect on fatigue patterns for the past week. To calculate the Global Fatigue Index (GFI): Convert item #15 to a 0-10 scale by multiplying each score by 2.5 and then sum items #1, 2, 3, average #4-14, and newly scored item #15. Scores range from 1 (no fatigue) to 50 (severe fatigue). Do not assign a score to items #4-14 if respondent indicated they "do not do any activity for reasons other than fatigue." If respondents select no fatigue on item #1, assign a zero to items #2-16. Item #16 is not included in the Global Fatigue Index.
Time frame: week 12
Time to Failure (Days)
Patients will be monitored for addition of any DMARD or withdrawal due to flare. The time to failure is defined as the duration of study participation (in days) until a qualifying event or completion of study treatment, whichever comes first.
Time frame: Baseline to 12 weeks
| Milestone | Prednisolone | Dipyridamole | Prednisone | Z102 | Placebo |
|---|---|---|---|---|---|
| Started | 32 | 41 | 18 | 84 | 83 |
| Completed | 25 | 28 | 16 | 64 | 65 |
| Not completed | 7 | 13 | 2 | 20 | 18 |
The primary efficacy endpoint was the mean change in Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12. The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤3.2 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.
| units on a scale | Prednisolone | Dipyridamole | Prednisone | Z102 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in DAS28-CRP at 12 Weeks | -1.147 ± 0.235 | -0.813 ± 0.216 | -1.237 ± 0.296 | -0.907 ± 0.149 | -0.538 ± 0.153 |
The mean change in the individual components of the Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12 which included individual assessment of Tender Joint Count (28-joint assessment), Swollen Joint Count (28-joint assessment), Patient Global Assessment of Disease Activity and absolute CRP level. In each case, higher scores indicate more disease activity. The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity.
No measurements were reported for this outcome.
The American College of Rheumatology (ACR) 20 is a widely accepted composite index of improvement in RA proposed by the ACR (Fransen and van Riel 2009). ACR20 refers to a composite improvement of 20% in swollen joint count, tender joint count, and 3 or more of the following 5 measures:Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient Pain VAS, Patient's self-addressed disability (HAQ) (Arnet 1988 and Felson 1995), Acute-phase reactant (ESR or CRP) The ACR 50 and ACR 70 are similar tools, used to indicate 50% and 70% improvement, respectively.
No measurements were reported for this outcome.
The Multidimensional Assessment of Fatigue (MAF) scale contains 16 items and measures four dimensions of fatigue: severity (#1-2), distress (#3), degree of interference in activities of daily living (#4-14), and timing (#15-16). Fourteen items contain numerical rating scales (#1-14) and two items have multiple-choice responses (#15-16). Respondents are asked to reflect on fatigue patterns for the past week. To calculate the Global Fatigue Index (GFI): Convert item #15 to a 0-10 scale by multiplying each score by 2.5 and then sum items #1, 2, 3, average #4-14, and newly scored item #15. Scores range from 1 (no fatigue) to 50 (severe fatigue). Do not assign a score to items #4-14 if respondent indicated they "do not do any activity for reasons other than fatigue." If respondents select no fatigue on item #1, assign a zero to items #2-16. Item #16 is not included in the Global Fatigue Index.
No measurements were reported for this outcome.
Patients will be monitored for addition of any DMARD or withdrawal due to flare. The time to failure is defined as the duration of study participation (in days) until a qualifying event or completion of study treatment, whichever comes first.
No measurements were reported for this outcome.
Collected over Adverse event data were collected from the time of consent through the end of study visit at 12 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prednisolone | — | 1/32 (3.1%) | 6/32 (18.8%) |
| Dipyridamole | — | 2/41 (4.9%) | 30/41 (73.2%) |
| Prednisone | — | 0/18 (0%) | 5/18 (27.8%) |
| Z102 | — | 5/84 (6%) | 38/84 (45.2%) |
| Placebo | — | 4/83 (4.8%) | 33/83 (39.8%) |
| Event | Prednisolone | Dipyridamole | Prednisone | Z102 | Placebo |
|---|---|---|---|---|---|
| Oedema PeripheralGeneral disorders | 1/32 | 0/41 | 0/18 | 0/84 | 0/83 |
| Angina PectorisCardiac disorders | 0/32 | 1/41 | 0/18 | 0/84 | 0/83 |
| Calculus UretericRenal and urinary disorders | 0/32 | 1/41 | 0/18 | 0/84 | 0/83 |
| SciaticaNervous system disorders | 0/32 | 0/41 | 0/18 | 2/84 | 1/83 |
| Haemolytic AnaemiaBlood and lymphatic system disorders | 0/32 | 0/41 | 0/18 | 0/84 | 1/83 |
| Ureteric ObstructionRenal and urinary disorders | 0/32 | 0/41 | 0/18 | 0/84 | 1/83 |
| Deep Vein ThrombosisVascular disorders | 0/32 | 0/41 | 0/18 | 0/84 | 1/83 |
| Hip FractureInjury, poisoning and procedural complications | 0/32 | 0/41 | 0/18 | 1/84 | 0/83 |
| Humerus FractureInjury, poisoning and procedural complications | 0/32 | 0/41 | 0/18 | 1/84 | 0/83 |
| Rheumatoid ArthritisMusculoskeletal and connective tissue disorders | 0/32 | 0/41 | 0/18 | 1/84 | 0/83 |
| Event | Prednisolone | Dipyridamole | Prednisone | Z102 | Placebo |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/32 | 11/41 | 0/18 | 13/84 | 4/83 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/32 | 3/41 | 1/18 | 5/84 | 8/83 |
| Rheumatoid ArthritisMusculoskeletal and connective tissue disorders | 0/32 | 3/41 | 1/18 | 5/84 | 4/83 |
| Back PainMusculoskeletal and connective tissue disorders | 1/32 | 3/41 | 0/18 | 1/84 | 1/83 |
| Abdominal Upper PainGastrointestinal disorders | 1/32 | 3/41 | 0/18 | 1/84 | 1/83 |
| NauseaGastrointestinal disorders | 0/32 | 2/41 | 1/18 | 3/84 | 1/83 |
| DiarrhoeaGastrointestinal disorders | 0/32 | 1/41 | 1/18 | 2/84 | 1/83 |
| NasopharyngitisInfections and infestations | 1/32 | 1/41 | 1/18 | 1/84 | 4/83 |
| VertigoEar and labyrinth disorders | 0/32 | 2/41 | 0/18 | 1/84 | 0/83 |
| Oedema PeripheralGeneral disorders | 1/32 | 0/41 | 0/18 | 0/84 | 2/83 |
population randomized to double blind phase of study and recieved at least one dose of study drug
| Age, Continuous(years) | Prednisolone | Dipyridamole | Prednisone | Z102 | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 55.2 ± 12.69 | 55.9 ± 9.35 | 55.5 ± 9.82 | 54.5 ± 11.53 | 53.7 ± 12.44 | 54.6 ± 11.5 |
| Sex: Female, Male(Participants) | Prednisolone | Dipyridamole | Prednisone | Z102 | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 26 | 36 | 17 | 72 | 75 | 226 |
| Male | 6 | 5 | 1 | 12 | 8 | 32 |
The record gives a start of Jun 2011, a primary completion of Aug 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prednisolone
Zalicus